Hidradenitis Suppurativa Treatment Guidelines

Disease Severity and Treatment Selection

• The British Journal of Dermatology recommends oral tetracycline (e.g., lymecycline 408 mg or doxycycline 100 mg) once or twice daily for 12 weeks for moderate disease 1
• The British Journal of Dermatology suggests alternative first-line treatment with tetracycline 500 mg twice daily or doxycycline 100 mg once or twice daily for up to 4 months for more widespread mild disease 1
• The British Journal of Dermatology recommends clindamycin 300 mg twice daily with rifampicin 300-600 mg daily for 10-12 weeks as a second-line treatment for moderate disease 1
• Consider treatment break after antibiotic courses to assess need for ongoing therapy and limit antimicrobial resistance, as recommended by the British Journal of Dermatology 1

Treatment Options for Severe Disease

• The British Journal of Dermatology recommends acitretin 0.3-0.5 mg/kg/day as an alternative option for patients unresponsive to adalimumab 1
• The British Journal of Dermatology suggests dapsone as an alternative option for patients unresponsive to adalimumab 1
• The British Journal of Dermatology recommends surgical intervention as an alternative option for patients unresponsive to adalimumab 1

Surgical Interventions

• The British Journal of Dermatology recommends radical surgical excision for extensive disease with sinus tracts and scarring 1
• The British Journal of Dermatology suggests healing by secondary intention, TDAP flap, or other reconstructive methods 1

Adjunctive Therapies

• The British Journal of Dermatology recommends screening for depression/anxiety 1
• The British Journal of Dermatology suggests screening for treatable cardiovascular risk factors (measure BP, lipids, HbA1c) 1

Monitoring and Follow-up

• The British Journal of Dermatology recommends assessing treatment response after 12 weeks using HiSCR and patient-reported outcomes 1

Treatment Limitations

• The British Journal of Dermatology states that there is insufficient evidence to recommend numerous therapies, including alitretinoin, anakinra, apremilast, atorvastatin, azathioprine, ciclosporin, colchicine, cyproterone, finasteride, fumaric acid esters, hydrocortisone, hyperbaric oxygen therapy, intravenous antibiotics, isoniazid, laser and photodynamic therapies, methotrexate, oral prednisolone, oral zinc, phototherapy, photochemotherapy, radiotherapy, secukinumab, spironolactone, staphage lysate, tolmetin sodium, and ustekinumab 1
• The British Journal of Dermatology recommends against cryotherapy and microwave ablation for treating lesions during the acute phase 1

Hidradenitis Suppurativa Treatment Guidelines

Disease Assessment and Treatment Algorithm

• The American Academy of Dermatology recommends evaluating disease severity using the Hurley staging system to guide appropriate treatment selection 2
• The treatment of hidradenitis suppurativa should follow a stepwise approach based on disease severity, with topical clindamycin for mild disease, oral antibiotics for moderate disease, and adalimumab for severe or refractory cases 3, 4
• Monitor treatment response using the Hidradenitis Suppurativa Clinical Response (HiSCR), which measures reduction in inflammatory lesions 3, 5
• Assess patient-reported outcomes including pain and quality of life 2

Treatment Options

• For mild disease, first-line therapy is topical clindamycin 1% solution/gel twice daily for 12 weeks 3, 4
• For moderate disease, first-line therapy is clindamycin 300 mg twice daily with rifampicin 600 mg once daily for 10-12 weeks 3, 5
• For severe disease, first-line therapy is adalimumab, with an initial dose of 160 mg, followed by 80 mg, then 40 mg weekly starting at day 29 3, 5
• Infliximab 5 mg/kg at weeks 0, 2, 6, and every 2 months thereafter for 12 weeks is considered for patients who fail adalimumab 3, 5

Surgical Interventions

• Surgical treatment is often necessary for lasting cure, especially in advanced disease 3, 5
• Options include deroofing for recurrent nodules and tunnels 2 and radical surgical excision for severe disease with extensive sinus tracts and scarring 3, 5

Special Populations

• For children aged 12 years and older with moderate to severe disease, adalimumab is FDA-approved 6
• For children aged 8 years and older requiring systemic antibiotics, oral doxycycline is recommended 6

Adjunctive Therapies

• Weight loss should be encouraged for patients with obesity 2
• Smoking cessation is important as tobacco use is associated with worse outcomes 2, 7
• Pain management with NSAIDs for symptomatic relief 7
• Appropriate wound care for draining lesions 7

Monitoring and Follow-up

• Assess treatment response using HiSCR, which measures reduction in inflammatory lesions 3, 2
• Evaluate quality of life improvement using DLQI 2
• Be aware that non-surgical methods rarely result in lasting cure for advanced disease 3, 5
• For adalimumab, if clinical response is not achieved after 16 weeks, consider alternative treatments 3, 5

Hidradenitis Suppurativa Treatment Guidelines

Disease Severity and Treatment Selection

• The American Academy of Dermatology recommends first-line therapy with topical clindamycin 1% solution/gel twice daily for 12 weeks for mild disease, with choice of skin cleanser being empiric, and intralesional triamcinolone (10 mg/mL) can be used for inflamed lesions, showing significant reduction in erythema, edema, suppuration, and pain 8
• For moderate disease, the American Academy of Dermatology recommends first-line therapy with tetracycline 500 mg twice daily for up to 4 months, and second-line therapy with clindamycin 300 mg twice daily with rifampicin 300-600 mg daily for 10-12 weeks 9

Biologic Therapies

• The American Academy of Dermatology recommends first-line biologic therapy with adalimumab 160 mg at week 0, 80 mg at week 2, then 40 mg weekly starting at week 4 for severe or refractory cases 9
• Second-line biologic therapy with infliximab 5 mg/kg at weeks 0, 2, 6, and every 2 months thereafter for 12 weeks is also recommended 9

Surgical Interventions

• Radical surgical excision is recommended for extensive disease with sinus tracts and scarring, with the width of the excision influencing therapeutic outcome 9
• Options for wound closure include secondary intention healing, skin grafts, or flaps 9

Hidradenitis Suppurativa Treatment Guidelines

Medication Therapy

• The American Academy of Dermatology recommends topical clindamycin 1% solution/gel twice daily for 12 weeks as first-line therapy for mild disease, and intralesional triamcinolone can be used for inflamed lesions, showing significant reduction in symptoms 10
• The American Academy of Dermatology suggests clindamycin 300 mg twice daily with rifampicin 300-600 mg daily for 10-12 weeks as second-line therapy for moderate disease 10
• Dapsone, starting at 50 mg daily and titrating up to 200 mg daily, can be considered as an alternative option for patients unresponsive to adalimumab 10
• Ertapenem 1g daily for 6 weeks can be considered as rescue therapy or during surgical planning for severe disease requiring IV antibiotics 10

Treatment of Hidradenitis Suppurativa

Disease Assessment and Treatment Algorithm

• The American Academy of Dermatology recommends first-line therapy with topical clindamycin 1% solution/gel twice daily for 12 weeks for mild disease, with options including chlorhexidine, benzoyl peroxide, and zinc pyrithione as skin cleansers 11
• Intralesional triamcinolone (10 mg/mL) can be used for inflamed lesions, showing significant reduction in erythema, edema, suppuration, and pain, according to the Journal of the American Academy of Dermatology 11

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Treatment Options

• The American Academy of Dermatology recommends topical clindamycin 1% solution/gel twice daily for 12 weeks as first-line therapy for mild disease, with adjunctive skin cleansers such as chlorhexidine, benzoyl peroxide, and zinc pyrithione 12
• Intralesional triamcinolone (10 mg/mL, 0.2-2.0 mL) can be used for inflamed lesions, showing significant reduction in erythema, edema, suppuration, and pain, as suggested by the Journal of the American Academy of Dermatology 12, 13
• Resorcinol 15% cream can reduce pain and duration of abscesses, though irritant dermatitis is a common side effect, according to the Journal of the American Academy of Dermatology 12, 14

Moderate Disease Treatment

• The American Academy of Dermatology suggests clindamycin 300 mg twice daily with rifampicin 300-600 mg daily for 10-12 weeks as second-line therapy for moderate disease 12, 13, 14
• Treatment typically lasts 8 to 12 weeks and can be repeated intermittently, as recommended by the Journal of the American Academy of Dermatology 12

Treatment Considerations

• Topical clindamycin may increase rates of Staphylococcus aureus resistance; consider combining with benzoyl peroxide to reduce this risk, as advised by the Journal of the American Academy of Dermatology 12, 13, 14

Doxycycline Treatment Duration for Hurley Stage 2 Hidradenitis Suppurativa

Treatment Recommendations

• For Hurley stage 2 hidradenitis suppurativa, the American Academy of Dermatology recommends doxycycline 100 mg twice daily for up to 4 months as first-line monotherapy, though it is not independently linked to better outcomes and clindamycin plus rifampicin is the preferred regimen for this stage 15, 16, 17
• The American Academy of Dermatology suggests that doxycycline 100 mg once or twice daily can be continued for up to 4 months (12-16 weeks) for more widespread mild disease or mild Hurley stage II disease 18
• Clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks is the superior first-line choice for Hurley stage 2 disease, according to the American Academy of Dermatology 15, 16, 17

Treatment Efficacy and Duration

• Response rates of 71-93% have been documented in systematic reviews for the clindamycin-rifampicin combination, far superior to doxycycline monotherapy, as reported by the American Academy of Dermatology 15, 16
• This regimen can be repeated intermittently as monotherapy in patients with mild-to-moderate disease or as adjuvant therapy in those with severe disease, according to the American Academy of Dermatology 15, 16
• Treatment typically lasts 8-12 weeks and demonstrates significantly better outcomes for abscesses and inflammatory nodules characteristic of Hurley stage 2, as reported by the American Academy of Dermatology 15, 16

Treatment Assessment and Escalation

• If no clinical response is achieved after 12 weeks of doxycycline, other treatment modalities must be considered, such as escalation to triple therapy (moxifloxacin + metronidazole + rifampin) or biologics, as suggested by the American Academy of Dermatology and Reviews in Endocrine and Metabolic Disorders 15, 18
• Do not continue doxycycline beyond 4 months without reassessment, as prolonged use increases antimicrobial resistance risk without proven additional benefit, according to Reviews in Endocrine and Metabolic Disorders 18
• Do not use doxycycline as first-line for Hurley stage 2 with deep inflammatory lesions or abscesses, as it has minimal effect on these lesions, as reported by the American Academy of Dermatology 15, 17

Medical Necessity for Infliximab in Severe Refractory Hidradenitis Suppurativa

Patient Eligibility Criteria

• The American Academy of Dermatology suggests that patients with hidradenitis suppurativa who have failed multiple prior therapies, including antibiotics and biologics, may be eligible for infliximab treatment 19, 20, 21
• Patients with Hurley Stage III disease, characterized by fistulous tracts, scarring, and chronic wounds, require aggressive medical management to prevent further morbidity and preserve quality of life 19

Guideline-Supported Treatment

• The 2025 North American Clinical Practice Guidelines explicitly support infliximab use in patients 6 years and older with hidradenitis suppurativa requiring biologics, with a conditional strength and moderate quality evidence 19, 20, 21
• The American Academy of Dermatology recommends infliximab 5 mg/kg at weeks 0, 2, 6, and every 2 months for patients who fail adalimumab, with higher doses and more frequent intervals supported for severe refractory cases 19

Dual Biologic Therapy

• The use of secukinumab in combination with infliximab is supported by the American Academy of Dermatology for patients with treatment-refractory disease, targeting different inflammatory pathways 19, 20, 22
• Secukinumab is suggested for patients 6 years and older with hidradenitis suppurativa requiring biologics, with a response rate of 64.5-71.4% in adalimumab-failure patients at 16-52 weeks 19, 20, 22

Hidradenitis Suppurativa Treatment Guidelines

Initial Assessment and Treatment

• The British Association of Dermatologists recommends examining all intertriginous areas to determine Hurley stage and total disease burden 23, 24
• The British Association of Dermatologists suggests documenting baseline pain using Visual Analog Scale (VAS) and inflammatory lesion count 23, 24
• The British Association of Dermatologists advises screening for comorbidities such as depression/anxiety, diabetes, hypertension, hyperlipidemia, and inflammatory bowel disease 23, 24

Topical Therapy Regimen

• The American Academy of Dermatology recommends topical clindamycin 1% solution applied twice daily to all affected areas for 12 weeks 25, 23, 24
• The American Academy of Dermatology suggests combining topical clindamycin with benzoyl peroxide wash or chlorhexidine 4% wash daily to reduce Staphylococcus aureus resistance risk 25, 23

Systemic Antibiotic Therapy

• The British Association of Dermatologists recommends doxycycline 100 mg once or twice daily for 12-16 weeks as a first-line oral antibiotic 23, 24
• The British Association of Dermatologists suggests lymecycline 408 mg once or twice daily for 12 weeks as an alternative first-line oral antibiotic 23, 24
• The American Academy of Dermatology recommends clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks as a second-line combination therapy 25, 23, 24

Treatment Assessment and Escalation

• The British Association of Dermatologists recommends reassessing patients at 12 weeks using pain VAS score, inflammatory lesion count, and quality of life measures (DLQI) 23, 24
• The American Academy of Dermatology suggests escalating to clindamycin 300 mg + rifampicin 300 mg twice daily for 10-12 weeks if there is an inadequate response after 12 weeks of tetracyclines 25, 23, 24

Adjunctive Measures

• The American Academy of Dermatology recommends intralesional triamcinolone 10 mg/mL for acutely inflamed nodules to provide rapid symptom relief within 1 day 25
• The British Association of Dermatologists advises essential lifestyle modifications, including smoking cessation referral, weight management referral if BMI elevated, appropriate wound dressings for draining lesions, and pain management with NSAIDs 23, 24

Hidradenitis Suppurativa Treatment Guidelines

Disease Severity Assessment and Treatment Algorithm

• The American Academy of Dermatology recommends determining disease severity using the Hurley staging system, with Hurley Stage I characterized by isolated nodules and abscesses without sinus tracts or scarring 26
• For mild disease (Hurley Stage I), the American Academy of Dermatology recommends first-line therapy with topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks 26
• For moderate disease (Hurley Stage II), the American Academy of Dermatology recommends first-line therapy with clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks 26
• For severe or refractory disease (Hurley Stage III or failed antibiotics), the American Academy of Dermatology recommends first-line biologic therapy with adalimumab, with a dosing schedule of 160 mg at week 0, 80 mg at week 2, and 40 mg weekly starting week 4 26

Surgical Interventions

• The American College of Surgeons recommends surgery as often necessary for lasting cure, especially in advanced disease with sinus tracts and scarring, with options including deroofing, radical surgical excision, and wound closure 26

Special Populations

• For adolescents 12 years and older with moderate to severe disease, the FDA recommends adalimumab with weight-based dosing, with a strength of evidence of high 26

Adjunctive Therapies and Comorbidity Management

• The American Heart Association recommends screening all patients for cardiovascular risk factors, including blood pressure, lipids, and HbA1c, with a strength of evidence of high 26

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Doxycycline Therapy

• The American Academy of Dermatology recommends doxycycline 100 mg once or twice daily for 12 weeks as a reasonable first-line oral antibiotic option for mild-to-moderate hidradenitis suppurativa (Hurley Stage I-II) 27, 28
• Doxycycline monotherapy is not recommended as first-line for Hurley Stage II disease with abscesses or inflammatory nodules, according to the American Academy of Dermatology 27, 28

Role in Treatment Algorithm

• For mild disease (Hurley Stage I), the British Association of Dermatologists suggests doxycycline 100 mg once or twice daily for 12 weeks as an acceptable first-line oral antibiotic after topical clindamycin 1% has been tried 29
• Alternative tetracycline options include lymecycline 408 mg once or twice daily for 12 weeks, as recommended by the British Association of Dermatologists 29
• Tetracycline 500 mg twice daily demonstrated only a 30% reduction in abscesses in a single RCT comparing it to topical clindamycin, with no significant improvement in patient-reported outcomes, according to the American Academy of Dermatology 27, 28

Evidence Quality and Limitations

• The evidence supporting doxycycline in hidradenitis suppurativa is notably weak, with only one RCT existing that compares tetracycline to topical clindamycin, showing modest 30% abscess reduction, as reported by the American Academy of Dermatology 27, 28
• Doxycycline has been evaluated primarily in combination with biologics (PIONEER studies), where it showed no independent benefit, according to the American Academy of Dermatology 27, 28

Treatment Duration and Monitoring

• The British Association of Dermatologists recommends treating for 12 weeks initially, then reassessing using pain VAS score, inflammatory lesion count, and quality of life measures (DLQI) 29
• Treatment can be extended up to 4 months (16 weeks) for more widespread mild disease, as suggested by the American Academy of Dermatology 28

When to Escalate Treatment

• If no clinical response after 12 weeks of doxycycline, consider escalating to clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks, according to the American Academy of Dermatology 27
• Refer to dermatology for consideration of biologics (adalimumab) or surgical intervention, as recommended by the British Association of Dermatologists 29

Critical Pitfalls to Avoid

• Do not use doxycycline as first-line for Hurley Stage II with deep inflammatory lesions or abscesses, as it has minimal effect on these lesions, according to the American Academy of Dermatology 27, 28
• Avoid long-term antibiotic use without treatment breaks to reduce antimicrobial resistance risk, as suggested by the British Association of Dermatologists 29

Adjunctive Measures

• Regardless of antibiotic choice, always address smoking cessation referral, weight management referral if BMI elevated, pain management with NSAIDs for symptomatic relief, appropriate wound dressings for draining lesions, and screen for depression/anxiety and cardiovascular risk factors (BP, lipids, HbA1c), as recommended by the British Association of Dermatologists 29

Treatment Options After Adalimumab Failure in Hidradenitis Suppurativa

Second-Line Biologic Therapy

• The American Academy of Dermatology suggests secukinumab for patients 6 years and older with conditional strength and moderate quality evidence as an alternative biologic option after adalimumab failure 30
• Ustekinumab is suggested for patients 6 years and older with conditional strength and moderate quality evidence as an alternative biologic option after adalimumab failure, representing an alternative pathway targeting different cytokines than TNF-alpha 30

Alternative Biologic Options

• Secukinumab demonstrates response rates of 64.5-71.4% in adalimumab-failure patients at 16-52 weeks, and can be used in combination with infliximab for treatment-refractory disease, targeting different inflammatory pathways 30
• Ustekinumab is an alternative biologic option after adalimumab failure, with conditional strength and moderate quality evidence, and can be used for patients 6 years and older 30

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Treatment Escalation

• The American Academy of Dermatology recommends clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks as second-line therapy for moderate disease after doxycycline failure, with response rates of 71-93% 31
• For severe disease or no clinical response after 12 weeks of clindamycin-rifampicin, escalate directly to adalimumab, which is FDA-approved for moderate-to-severe HS in patients ≥12 years old 31

Assessment and Adjunctive Measures

• The American Academy of Dermatology suggests reassessing patients using objective measures, including HiSCR (≥50% reduction in abscess/nodule count with no increase in abscesses or draining fistulas) at 12 weeks 32
• Smoking cessation referral and weight management referral are recommended, as tobacco use and obesity worsen outcomes 31, 32
• Pain management with NSAIDs is suggested for symptomatic relief 31

Biologic Therapy

• Adalimumab dosing is recommended as 160 mg at week 0, 80 mg at week 2, then 40 mg weekly starting at week 4, with HiSCR response rates of 42-59% at week 12 31
• If adalimumab fails, second-line biologic options include infliximab 5 mg/kg at weeks 0, 2, 6, then every 2 months, secukinumab, and ustekinumab, which target different cytokine pathways 31, 32

Surgical Considerations

• Surgical deroofing or radical excision should be considered concurrently with medical therapy for extensive disease with sinus tracts and scarring, as combining adalimumab with surgery results in greater clinical effectiveness than adalimumab monotherapy 31

Hidradenitis Suppurativa Treatment Guidelines

First-Line Treatment

• The American Academy of Dermatology recommends clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks, combined with intralesional triamcinolone 10 mg/mL for acutely inflamed nodules, as first-line treatment for Hurley Stage II hidradenitis suppurativa with active axillary and inguinal abscesses 33
• Clindamycin 300 mg orally twice daily PLUS rifampicin 300-600 mg orally once or twice daily for 10-12 weeks achieves response rates of 71-93% in systematic reviews, far superior to tetracycline monotherapy (30% abscess reduction) 33
• Intralesional triamcinolone 10 mg/mL (0.2-2.0 mL) injected directly into inflamed nodules and abscesses provides rapid symptom relief within 1 day, with significant reductions in erythema, edema, suppuration, lesion size, and pain VAS scores 33

Second-Line Treatment

• The American Academy of Dermatology recommends adalimumab 160 mg subcutaneous at week 0, 80 mg at week 2, then 40 mg weekly starting at week 4, as second-line treatment for moderate-to-severe hidradenitis suppurativa with inadequate response to first-line treatment 33
• Adalimumab dosing achieves HiSCR response rates of 42-59% at week 12 in placebo-controlled trials, with 59% achieving HiSCR at week 12 versus 28% with placebo in Study HS-II 33

Critical Pitfalls to Avoid

• Do NOT use doxycycline or tetracycline monotherapy as first-line for Hurley Stage II with abscesses, as these have minimal effect on deep inflammatory lesions and abscesses, showing only 30% abscess reduction 33
• Do NOT use topical clindamycin alone for Hurley Stage II hidradenitis suppurativa, as it only reduces superficial pustules, not inflammatory nodules or abscesses 33

Surgical Considerations

• Radical surgical excision may be necessary for extensive disease with sinus tracts and scarring that fails medical management, with the American Academy of Dermatology recommending consideration of surgery for lasting cure, especially in advanced disease 33

Tetracycline Use in Hidradenitis Suppurativa

Disease Severity Assessment and Treatment

• The American Academy of Dermatology recommends tetracycline 500 mg twice daily for up to 4 months as first-line oral antibiotic therapy for moderate Hidradenitis Suppurativa (more widespread Hurley Stage I or mild Hurley Stage II) without deep inflammatory lesions or abscesses 34, 35
• The American Academy of Dermatology suggests assessing Hurley staging, as tetracyclines are effective for Hurley I (isolated nodules without sinus tracts) or mild Hurley II (recurrent nodules with limited sinus tracts) 34, 35
• The American Academy of Dermatology advises against using tetracyclines as first-line therapy for Hurley Stage II with abscesses or deep inflammatory nodules, as they have minimal effect on these lesions, showing only 30% abscess reduction in a single RCT comparing tetracycline to topical clindamycin 35

Specific Tetracycline Regimens

• The American Academy of Dermatology recommends tetracycline 500 mg twice daily for up to 4 months (12-16 weeks) 34, 35
• The American Academy of Dermatology suggests doxycycline 100 mg once or twice daily for 12 weeks as an alternative first-line option 35

Treatment Escalation

• The American Academy of Dermatology recommends escalating to clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks if no clinical response after 12 weeks of tetracyclines 35
• The American Academy of Dermatology advises escalating to adalimumab (160 mg week 0, 80 mg week 2, then 40 mg weekly starting week 4) if clindamycin-rifampicin fails after 12 weeks 34

Evidence Limitations

• The evidence quality is weak (Level IIb), based primarily on a single double-blind trial of 46 patients comparing tetracycline to topical clindamycin, showing modest 30% abscess reduction with no significant improvement in patient-reported outcomes 34, 35
• Tetracyclines performed no better than topical clindamycin 1% in the only head-to-head comparison 34

Hidradenitis Suppurativa Treatment Guidelines

Initial Assessment and Treatment

• The British Journal of Dermatology recommends beginning with Hurley staging assessment, then initiating topical clindamycin 1% twice daily for Hurley Stage I disease, oral tetracycline for 12 weeks for moderate disease, or immediate referral to dermatology for Hurley Stage III disease 36
• Record Hurley stage for the worst affected regions to determine the treatment pathway, as recommended by the British Journal of Dermatology 36

Treatment by Disease Severity

• For Hurley Stage I, the British Journal of Dermatology recommends first-line therapy with topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks 36
• For Hurley Stage II, the British Journal of Dermatology recommends first-line therapy with oral tetracycline, such as doxycycline 100 mg once or twice daily, for 12 weeks 36
• For Hurley Stage III, the British Journal of Dermatology recommends immediate referral to dermatology and consideration of clindamycin 300 mg twice daily plus rifampicin 300 mg twice daily while awaiting specialist evaluation 36

Mandatory Adjunctive Measures

• The British Journal of Dermatology recommends smoking cessation referral, weight management referral, pain management with NSAIDs, appropriate wound dressings, screening for depression/anxiety, and screening for cardiovascular risk factors for all patients with hidradenitis suppurativa 36

Reassessment and Treatment Escalation

• The British Journal of Dermatology recommends reassessing treatment response at 12 weeks using pain VAS score, inflammatory lesion count, number of flares, and quality of life (DLQI) 36
• If no response after 12 weeks of first-line therapy, the British Journal of Dermatology recommends escalating to clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks 36

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Treatment

• The British Journal of Dermatology recommends topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks for mild disease (Hurley Stage I) 37
• For moderate disease (Hurley Stage II), the Journal of the American Academy of Dermatology suggests clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks, achieving response rates of 71-93% 37, 38

First-Line Antibiotic Therapy

• The American Academy of Dermatology recommends doxycycline 100 mg once or twice daily for 12 weeks as an alternative first-line option for widespread mild disease or mild Hurley Stage II without deep inflammatory lesions 37
• For pediatric patients ≥8 years old, the Journal of the American Academy of Dermatology suggests doxycycline 100 mg once or twice daily, or clindamycin 300 mg twice daily plus rifampicin 300 mg twice daily for 10-12 weeks 38
• For breastfeeding patients, the Journal of the American Academy of Dermatology recommends amoxicillin/clavulanic acid, erythromycin, azithromycin, or metronidazole, and limiting doxycycline to ≤3 weeks without repeating courses 38

Biologic Therapy

• The British Journal of Dermatology and the Journal of the American Academy of Dermatology recommend adalimumab (FDA-approved biologic for moderate-to-severe HS) as a treatment option, with HiSCR response rates of 42-59% at week 12 37, 38
• The Journal of the American Academy of Dermatology suggests infliximab, secukinumab, and ustekinumab as second-line biologic options after adalimumab failure 37, 38

Special Considerations

• The Journal of the American Academy of Dermatology recommends avoiding rifampicin in patients with HIV due to drug interactions with certain HIV therapies, and using doxycycline for added prophylactic benefit against bacterial STIs 38, 39
• The British Journal of Dermatology and the Journal of the American Academy of Dermatology emphasize the importance of addressing smoking cessation, weight management, pain management, and wound dressings in all patients 37

Surgical Considerations

• The British Journal of Dermatology recommends radical surgical excision for extensive disease when conventional systemic treatments have failed, and combining adalimumab with surgery for greater clinical effectiveness 37

Hidradenitis Suppurativa Treatment Guidelines

Initial Assessment and Screening

• The British Journal of Dermatology recommends screening for comorbidities, including depression/anxiety, diabetes, hypertension, hyperlipidemia, and inflammatory bowel disease, in patients with hidradenitis suppurativa 40
• The British Journal of Dermatology suggests referring patients to smoking cessation services and weight management if relevant 40

Treatment by Disease Severity

• For mild disease (Hurley Stage I), the British Journal of Dermatology recommends topical clindamycin 1% twice daily for 12 weeks 40
• For moderate disease (Hurley Stage II), the British Journal of Dermatology recommends clindamycin 300 mg plus rifampicin 300-600 mg orally twice daily for 10-12 weeks 40
• For severe disease (Hurley Stage III) or failure of antibiotics, the British Journal of Dermatology recommends initiating adalimumab 160 mg at week 0, 80 mg at week 2, then 40 mg weekly starting week 4 40
• The British Journal of Dermatology recommends against using adalimumab 40 mg every other week for moderate-to-severe HS, as this dosing is ineffective 40

Alternative Systemic Therapies

• The British Journal of Dermatology recommends acitretin 0.3-0.5 mg/kg/day in males and non-fertile females as an alternative systemic therapy 40
• The British Journal of Dermatology suggests considering metformin in patients with concomitant diabetes or PCOS 40
• The British Journal of Dermatology recommends dapsone starting at 50 mg daily, titrating up to 200 mg daily, as an alternative systemic therapy 40

Surgical Interventions

• The British Journal of Dermatology recommends radical surgical excision for extensive disease with sinus tracts and scarring when conventional systemic treatments have failed 40
• The British Journal of Dermatology suggests combining adalimumab with surgery for greater clinical effectiveness than adalimumab monotherapy, although the specific citation for this is not provided, it is mentioned in the context of 40

Mandatory Adjunctive Measures

• The British Journal of Dermatology recommends pain management with NSAIDs for symptomatic relief 40
• The British Journal of Dermatology suggests using appropriate wound dressings for draining lesions 40
• The British Journal of Dermatology recommends screening for depression/anxiety and referring patients to smoking cessation services and weight management if relevant 40

Critical Pitfalls to Avoid

• The British Journal of Dermatology recommends against offering isotretinoin unless there are concomitant moderate-to-severe acneiform lesions of the face or trunk 40
• The British Journal of Dermatology recommends against offering etanercept for moderate-to-severe HS, as it is ineffective 40
• The British Journal of Dermatology suggests avoiding long-term antibiotic use without treatment breaks to reduce antimicrobial resistance risk 40

Oral Corticosteroids in Hidradenitis Suppurativa

Introduction to Oral Corticosteroid Use

• The American Academy of Dermatology recommends oral corticosteroids (prednisone) for acute, widespread flares of hidradenitis suppurativa, but not for routine or long-term management, with conditional strength and low-quality evidence 41, 42
• Oral corticosteroids should be reserved for patients who require rapid symptom control while awaiting response to definitive therapies, with a highly limited role in HS management 41, 42, 43

Special Population Considerations

• In patients with prior malignancy requiring systemic immunomodulators for HS, the American Academy of Dermatology suggests prednisone for acute, widespread flares, representing one of the safer immunosuppressive options for short-term use 41, 42
• For pediatric patients with HS requiring systemic immunomodulators, prednisone is suggested for acute, widespread flares only, with the same restrictions applying: short-term use for acute exacerbations, not maintenance therapy 43

Infection Risk and Screening

• If prednisone dose exceeds 15 mg daily for at least 4 weeks, annual screening for latent TB is mandatory, according to the American Academy of Dermatology, which is critical for infection risk stratification 41, 42

Treatment Algorithm and Guidelines

• The British Association of Dermatologists states there is insufficient evidence to recommend oral prednisolone for HS, while the 2025 North American guidelines upgraded this to a conditional suggestion for acute flares only, but still with low-quality evidence 44
• The American Academy of Dermatology suggests oral prednisone only if acute widespread flare occurs during treatment for moderate disease (Hurley Stage II) 41, 42
• Prednisone may be used as bridge therapy during biologic initiation for severe acute flares in patients with severe disease (Hurley Stage III) 41, 42

Critical Evidence Gaps and Limitations

• No randomized controlled trials exist evaluating oral corticosteroids specifically for HS, according to the British Journal of Dermatology 44
• The evidence supporting oral corticosteroids in HS is notably weak, with low-quality evidence and conditional recommendations 41, 42, 44

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Treatment

• The American Academy of Dermatology recommends adalimumab 40 mg weekly as maintenance therapy for severe or refractory hidradenitis suppurativa, with a HiSCR response rate of 42-59% at week 12 45

Biologic Therapy

• The National Institute for Health and Care Excellence recommends continuing adalimumab 40 mg weekly as long as hidradenitis suppurativa lesions are present and the patient maintains response, with a response rate of 42-59% at week 12 45
• The European Academy of Dermatology and Venereology suggests secukinumab as a second-line biologic option after adalimumab failure, with response rates of 64.5-71.4% in adalimumab-failure patients at 16-52 weeks 45

Post-Excision Antibiotic Therapy for Hidradenitis Suppurativa

Introduction to Treatment

• The British Association of Dermatologists recommends oral clindamycin 300 mg twice daily combined with rifampicin 300-600 mg daily for 10-12 weeks as the post-operative antibiotic regimen to prevent recurrence and manage residual disease in patients with hidradenitis suppurativa after excision surgery 46, 47

Rationale for Combination Therapy

• The clindamycin-rifampicin combination achieves response rates of 71-93% in systematic reviews, and is specifically recommended for moderate-to-severe HS, which characterizes most patients requiring surgical excision 46, 47, 48

Specific Dosing Regimen

• Clindamycin should be administered at 300 mg orally twice daily 46, 47, 48
• Rifampicin should be administered at 300-600 mg orally once daily (or 300 mg twice daily) 46, 47, 48
• The duration of treatment should be 10-12 weeks 46, 47, 48

Treatment Monitoring and Breaks

• Reassess treatment response at 12 weeks using pain VAS score, inflammatory lesion count, number of flares, and quality of life (DLQI) 46, 47
• Consider treatment breaks after completing the 10-12 week course to assess need for ongoing therapy and limit antimicrobial resistance risk 46, 47

Adverse Events and Monitoring

• Avoid long-term continuous antibiotic use without treatment breaks to reduce antimicrobial resistance risk 46, 47

Post-Operative Context

• The combination therapy is recommended for patients with extensive disease requiring surgical intervention, which inherently includes the post-operative period 46, 47

When to Escalate Beyond Antibiotics

• If no clinical response after 10-12 weeks of clindamycin-rifampicin combination therapy, escalate to biologic therapy with adalimumab 46, 47

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Treatment

• The American Academy of Dermatology recommends clindamycin 300 mg orally twice daily plus rifampicin 300-600 mg orally once or twice daily for 10-12 weeks as the best antibiotic regimen for moderate-to-severe hidradenitis suppurativa, achieving response rates of 71-93% 49
• For mild disease, the American Academy of Dermatology suggests starting with topical clindamycin 1% solution or gel applied twice daily to all affected areas for 12 weeks as first-line therapy for isolated nodules and abscesses without sinus tracts 49
• The American Academy of Dermatology recommends reassessing treatment response at 12 weeks using pain VAS score, inflammatory lesion count, number of flares, and quality of life (DLQI) 49
• Consider treatment breaks after completing the 10-12 week course to assess need for ongoing therapy and limit antimicrobial resistance risk, as recommended by the American Academy of Dermatology 49

Special Population Considerations

• For patients with HIV, the American Academy of Dermatology suggests using doxycycline due to added prophylactic benefit against bacterial STIs in this population 50
• The American Academy of Dermatology recommends exercising caution with rifampicin due to drug interactions with certain HIV therapies 50
• For patients with Hepatitis B or C, the American Academy of Dermatology suggests using doxycycline with standard approach for patients without cirrhosis 50
• The American Academy of Dermatology recommends exercising caution with rifampicin due to potential hepatotoxicity 50

Hidradenitis Suppurativa Treatment Guidelines

Initial Assessment and Diagnosis

• The American Academy of Dermatology recommends determining whether a patient has hidradenitis suppurativa (HS) or a simple bacterial abscess by looking for recurrent nodules or abscesses, comedones, sinus tracts or tunneling, and scarring, with a strong suspicion of HS in patients with peak incidence in the third-fourth decade and axillary location 51
• The Hurley stage should be determined to guide treatment intensity, with Stage I being isolated nodules/abscesses, Stage II being recurrent nodules with limited sinus tracts and scarring, and Stage III being multiple/extensive sinus tracts and scarring 51

First-Line Treatment for Moderate Disease

• The American Academy of Dermatology recommends oral clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks, combined with intralesional triamcinolone 10 mg/mL for acutely inflamed nodules, achieving response rates of 71-93% 52
• This combination is the preferred first-line regimen for moderate HS with active abscesses, with significant reductions in erythema, edema, suppuration, and pain 52

Biologic Therapy for Severe or Refractory Disease

• Adalimumab is the only FDA-approved biologic for moderate-to-severe HS, with dosing of 160 mg subcutaneous at week 0, 80 mg at week 2, and 40 mg weekly starting at week 4, achieving HiSCR response rates of 42-59% at week 12 52, 53
• If no clinical response after 16 weeks, consider second-line biologics such as infliximab, secukinumab, or ustekinumab 52

Surgical Considerations

• Radical surgical excision is recommended for extensive disease with sinus tracts and scarring when conventional systemic treatments have failed, with non-recurrence rates after wide excision of 81.25% 53
• Combining adalimumab with surgery results in greater clinical effectiveness than adalimumab monotherapy, and consider surgery concurrently with medical therapy for Hurley Stage II-III disease with established sinus tracts 53

Hidradenitis Suppurativa Treatment Guidelines

Disease Severity Assessment and Treatment

• The British Journal of Dermatology recommends determining Hurley stage by examining all intertriginous areas for features such as isolated nodules and abscesses, recurrent abscesses, and sinus tracts, to guide treatment decisions 54
• For mild disease (Hurley Stage I), the British Journal of Dermatology suggests topical clindamycin 1% solution applied twice daily to all affected areas for 12 weeks as first-line treatment 54
• For moderate disease (Hurley Stage II), the British Journal of Dermatology recommends oral clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks as first-line treatment, achieving response rates of 71-93% 54

Treatment Escalation and Adjunctive Measures

• The British Journal of Dermatology advises escalating to adalimumab 160 mg subcutaneous at week 0, 80 mg at week 2, then 40 mg weekly starting at week 4, for patients who fail antibiotic therapy after 12 weeks 54
• The British Journal of Dermatology recommends implementing adjunctive measures such as smoking cessation referral, weight management referral, pain management with NSAIDs, appropriate wound dressings, and screening for depression/anxiety and cardiovascular risk factors at baseline 54

Reassessment and Treatment Breaks

• The British Journal of Dermatology suggests reassessing treatment response using pain VAS score, inflammatory lesion count, number of flares, quality of life, and HiSCR at 12 weeks 54
• The British Journal of Dermatology recommends considering treatment breaks after completing 10-12 week antibiotic courses to assess need for ongoing therapy and limit antimicrobial resistance risk 54

Management of Hidradenitis Suppurativa – Evidence‑Based Recommendations

Diagnosis

• The American Academy of Dermatology states that hidradenitis suppurativa (HS) is diagnosed clinically by identifying recurrent painful nodules or abscesses in the inguinal region, with at least two episodes within six months 55.
• The presence of sinus tracts or tunneling beneath the skin surface indicates more advanced disease and is required for accurate staging 55.
• Bacterial cultures should not be ordered unless there are clear signs of secondary infection (e.g., cellulitis, fever), because mixed normal flora does not guide therapy 55.
• Genetic or biomarker testing has no current role in the diagnostic work‑up of HS 55.

Hurley Staging

• Stage I – Isolated nodules/abscesses with minimal or no scarring and no sinus tracts 55.
• Stage II – Recurrent nodules with one or limited sinus tracts and scarring within the groin region 55.
• Stage III – Multiple or extensive sinus tracts and scarring affecting the entire groin/genital area 55.
• Baseline documentation should include a Visual Analog Scale (VAS) for pain and a count of inflammatory lesions (nodules + abscesses) to monitor treatment response 55.

Mandatory Comorbidity Screening

• Smoking – 70–75 % of HS patients are smokers; document pack‑years and refer for cessation services 56.
• Diabetes – HS patients have a 1.5–3‑fold increased risk of diabetes, with prevalence up to 30 %; screen with HbA1c or fasting glucose [55][56].
• Metabolic syndrome – Measure blood pressure, lipid profile, and body‑mass index (BMI) at baseline 56.
• Psychiatric comorbidity – Screen for depression and anxiety using validated tools, as these conditions are common in HS [55][56].
• Inflammatory bowel disease – Perform a thorough review of gastrointestinal symptoms to detect possible IBD 56.
• Squamous cell carcinoma risk – Examine chronic perineal and buttock lesions carefully, as SCC is the most frequent malignancy in these sites 55.

Initial Treatment by Hurley Stage

Stage I (Mild Disease)

• First‑line therapy: topical clindamycin 1 % solution or gel applied twice daily to all affected groin areas for 12 weeks 55.

Stage II (Moderate Disease)

• First‑line systemic regimen: oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg once or twice daily for 10–12 weeks, achieving response rates of 71–93 % [55][56].

Stage III (Severe Disease)

• While awaiting specialist evaluation, initiate clindamycin 300 mg + rifampicin 300 mg twice daily 55.
• Definitive therapy includes adalimumab (160 mg week 0, 80 mg week 2, then 40 mg weekly from week 4) or surgical intervention 55.

Essential Adjunctive Measures (All Stages)

• Smoking‑cessation referral improves outcomes and reduces treatment failure 56.
• Weight‑management referral is advised when BMI is elevated; obesity prevalence exceeds 75 % in HS patients 56.

Reassessment and Escalation (12‑Week Review)

• Re‑evaluate pain using VAS, count inflammatory lesions, and assess HiSCR (≥50 % reduction in abscess/nodule count without new abscesses or draining fistulas) 55.
• If no clinical response after 12 weeks of first‑line therapy, escalate to the clindamycin‑rifampicin combination (if not already used) or to adalimumab for refractory disease 55.
• Antibiotic courses should be limited to 10–12 weeks with treatment breaks to minimize antimicrobial resistance [55][56].

Pitfalls to Avoid

• Avoid indefinite antibiotic use; limit courses to 10–12 weeks and reassess before continuation [55][56].

Management of Acute Hidradenitis Suppurativa Flare

Immediate Pharmacologic Management

• Initiate oral clindamycin 300 mg twice daily together with rifampicin 300–600 mg daily for a 10–12‑week course, and give a single intralesional injection of triamcinolone 10 mg/mL into each inflamed nodule to achieve rapid symptom relief (often within 24 hours) and response rates of 71‑93 % in moderate‑to‑severe flares. 57
• Provide NSAIDs for analgesia and apply appropriate wound dressings to draining lesions while the antibiotic regimen takes effect. 57

Treatment Duration and Monitoring

• Continue the clindamycin‑rifampicin combination for the full 10–12 weeks, then reassess disease activity using a pain visual‑analogue scale, count of inflammatory lesions, and quality‑of‑life measures. 57
• After completing the 10–12‑week course, consider a treatment break to evaluate the need for further therapy and to reduce the risk of antimicrobial resistance. 57

Criteria for Escalation Beyond Antibiotics

• If there is no clinical response after 12 weeks of the clindamycin‑rifampicin regimen, escalate to adalimumab with a loading dose of 160 mg subcutaneously at week 0, 80 mg at week 2, followed by 40 mg weekly starting at week 4. 57
• For severe, widespread acute flares, a short course of oral prednisone may be used as bridge therapy while awaiting response to definitive treatments; this should be limited to the acute episode and not used for maintenance. 58

Comprehensive Assessment During Flare

• Screen all patients for depression, anxiety, and cardiovascular risk factors (blood pressure, lipid profile, glycated hemoglobin) because these comorbidities are highly prevalent in hidradenitis suppurativa. 57

Common Pitfalls to Avoid

• Do not extend antibiotic therapy beyond 12 weeks without a formal reassessment, as prolonged use increases antimicrobial resistance without demonstrated additional benefit. 57
• Do not prescribe adalimumab 40 mg every other week for moderate‑to‑severe disease; weekly dosing (40 mg) is required for efficacy. 57

Epidemiology, Risk Factors, Classification, Diagnosis, and Management of Hidradenitis Suppurativa

Definition

• Hidradenitis suppurativa (HS) is a chronic, recurrent, debilitating inflammatory disease of the hair follicle that typically begins after puberty and is characterized by painful nodules, abscesses, comedones, sinus tracts, and scarring in intertriginous areas such as the axillae, inguinal, and anogenital regions. 59, 60

Epidemiology

• The prevalence of HS is estimated at 1–4 % of the general population worldwide, including the United Kingdom. 59
• Onset most commonly occurs in the second to fourth decade of life (ages 20–40). 59, 60
• There is a marked female predominance (approximately 3 : 1 female : male). 59, 61
• Prevalence is three‑fold higher in African‑American individuals and two‑fold higher in biracial individuals compared with white individuals. 59
• Lower socioeconomic status is associated with an increased risk of HS. 60

Modifiable Risk Factors

• Smoking and obesity are the two most important modifiable risk factors, with odds ratios of 36 for smoking and 33 for obesity compared with non‑affected controls. 59, 61
• 70–75 % of patients with HS are current smokers; nicotine promotes epidermal hyperplasia and follicular plugging. 62
• >75 % of HS patients are obese; excess adiposity increases mechanical friction in flexural sites and elevates pro‑inflammatory cytokines (e.g., IL‑1β, TNF‑α). 62
• Up to 42 % of patients report a positive family history, suggesting an autosomal‑dominant inheritance pattern in some families. 62
• Heterozygous mutations in γ‑secretase complex genes (NCSTN, PSEN1, PSENEN) have been identified in a subset of familial HS cases. 62

Pathophysiology (Key Concepts)

• Primary follicular occlusion is the initiating defect, leading to hyperkeratosis, follicular hyperplasia, dilation, rupture, and a robust perifollicular lymphohistiocytic inflammatory response. 62
• Aberrant immune activation underlies disease activity; anti‑TNF agents have demonstrated clinical benefit, supporting an immune‑mediated component. 62
• Hormonal influences are suggested by the female predominance, post‑pubertal onset, pre‑menstrual flares, and symptom improvement during pregnancy. 62
• Antibiotics may improve lesions primarily through anti‑inflammatory effects rather than direct antibacterial action. 62

Clinical Presentation

• Typical lesions include paired comedones, papules, pustules, nodules, cysts, abscesses, sinus tracts, and fistulas in flexural regions, with considerable phenotypic variability. 59, 61
• Severe pain is the cardinal symptom of HS. 59
• Additional symptoms: pruritus, chronic serous/purulent/bloody discharge, and persistent malodor. 59
• Most frequently affected sites (in order): axillae, inguinal/genital region, perianal/perineal area, sub‑mammary/inter‑mammary folds, buttocks/medial thighs, abdominal fold/retro‑auricular region. 59
• Chronic disease can lead to fibrosis, contractures, and scarring that reduce mobility. 59

Classification and Staging

• The Hurley staging system is recommended for routine clinical use because of its simplicity and utility in guiding therapy (American Academy of Dermatology). 60
  
  • Stage I – Recurrent nodules/abscesses with minimal or no scarring; no sinus tracts. 60
  • Stage II – One or a limited number of sinus tracts and/or scarring confined to a single anatomic region. 60
  • Stage III – Multiple or extensive sinus tracts and scarring involving an entire region. 60
• Hurley is a static score and lacks sensitivity to change; the Hidradenitis Suppurativa Clinical Response (HiSCR) (≥ 50 % reduction in inflammatory nodules/abscesses without increase in draining lesions) is now used in research and clinical trials. 62
• Pain is routinely quantified using a Visual Analogue Scale (VAS) or a 0‑10 numeric rating scale. 62
• Health‑related quality of life is assessed with the Dermatology Life Quality Index (DLQI) or Skindex. 62

Diagnosis

• Diagnosis is clinical; histopathology is not required. 62, 60
• Consensus diagnostic criteria require:

Management by Hurley Stage

Hurley Stage I (Mild Disease)

• Topical clindamycin 1 % solution or gel applied twice daily to all affected areas for 12 weeks. (Evidence level: moderate; response rates reported in clinical series.) 61

Hurley Stage II (Moderate Disease)

• First‑line oral regimen: Clindamycin 300 mg twice daily + rifampicin 300–600 mg once or twice daily for 10–12 weeks, achieving 71–93 % clinical response. (Evidence level: high; randomized controlled trials.) 61
• Alternative: Doxycycline 100 mg once or twice daily for 12 weeks for more extensive mild disease or Hurley II without deep inflammatory nodules; not recommended as monotherapy for Hurley II with abscesses (only ~30 % reduction in abscess count). (Evidence level: moderate.) 61

Hurley Stage III (Severe Disease)

• Bridge therapy while awaiting specialist assessment: Clindamycin 300 mg + rifampicin 300 mg twice daily. (Evidence level: moderate.) 61
• Definitive therapy: Adalimumab – loading dose 160 mg subcutaneously at week 0, 80 mg at week 2, then 40 mg weekly from week 4 onward; or surgical intervention. (Evidence level: high; FDA‑approved biologic for moderate‑to‑severe HS.) 61

Surgical Management (Advanced Disease)

• Wide excision of affected tissue yields a non‑recurrence rate of ~81 % after extensive resection. (Evidence level: moderate.) 59
• Wound closure options include secondary intention healing, split‑thickness skin grafts, or local flaps (e.g., thoracodorsal artery perforator flap). (Evidence level: moderate.) 59

Complications

• Fistula formation involving the urethra, bladder, or rectum. 62, 59
• Lymphedema of affected regions. 62, 59
• Anemia secondary to chronic inflammation. 62, 59
• Squamous cell carcinoma may arise in chronic perineal or gluteal lesions. 62
• Dermatologic contractures leading to reduced range of motion. 59

Impact on Quality of Life and Psychosocial Health

• In a cohort of 114 secondary‑care patients, the mean DLQI score was 8.9, indicating a moderate impact on quality of life. (Evidence level: moderate.) 62
• Persistent pain, chronic purulent discharge, and malodor contribute to substantial morbidity. (Evidence level: moderate.) 62, 59
• Patients with HS have a higher prevalence of depression and completed suicide compared with the general population. (Evidence level: moderate.) 59

Associated Comorbidities

• Cardiovascular disease: Mortality risk is nearly doubled compared with matched controls. (Evidence level: moderate.) 59
• Metabolic syndrome components – type 2 diabetes, hyperlipidemia, and hypertension are more common in HS patients. (Evidence level: moderate.) 59
• Inflammatory bowel disease: Strong association with Crohn disease, but not with ulcerative colitis. (Evidence level: moderate.) 59
• Pilonidal sinus may represent a phenotypic variant of HS. (Evidence level: low.) 59
• Acne vulgaris frequently co‑occurs with HS. (Evidence level: low.) 59

Guideline Recommendations for Antibiotic Combination with Adalimumab in Hidradenitis Suppurativa

Recommended Combination Therapy

• The 2025 North American Clinical Practice Guidelines endorse the concurrent use of clindamycin + rifampicin with adalimumab as standard therapy for patients with moderate hidradenitis suppurativa, indicating that this antibiotic regimen can be safely administered alongside biologic treatment. 63

Alternative Antibiotic Option

• Doxycycline may be combined with adalimumab in patients who are unable to tolerate clindamycin‑rifampicin or in special populations (e.g., individuals with HIV) where doxycycline offers additional prophylactic protection against bacterial sexually transmitted infections. 63

Second‑Line Biologic Therapy and Antibiotic Stewardship in Hidradenitis Suppurativa

Infliximab as a Rescue Biologic

• In patients with hidradenitis suppurativa who have failed adalimumab, a regimen of infliximab 5 mg/kg administered at weeks 0, 2, 6 and then every 2 months produced an average improvement of ≈ 8 points in the Dermatology Life Quality Index after eight weeks, indicating clinically meaningful benefit【64】.

Antibiotic Duration and Resistance Risk

• Prolonged courses of oral antibiotics for hidradenitis suppurativa should be avoided without a formal reassessment; limiting therapy to ≤ 12 weeks and incorporating treatment breaks helps reduce the risk of antimicrobial resistance【64】.

Antibiotic Management of Moderate Hidradenitis Suppurativa (Hurley Stage II)

First‑Line Systemic Therapy for Moderate Disease

• Oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg once or twice daily for 10–12 weeks produces clinical response rates of 71 %–93 % in patients with Hurley Stage II disease. The British Association of Dermatologists (BAD) 2019 guideline cites this regimen as the preferred first‑line option after tetracyclines fail, and the 2025 North American dermatology guidelines elevate it to a first‑line recommendation. Evidence level: systematic‑review data (high‑quality) and guideline endorsement 65

First‑Line Topical Therapy for Mild Disease (Hurley Stage I)

• Topical clindamycin 1 % solution or gel applied twice daily for 12 weeks is recommended as the initial treatment for isolated nodules or abscesses without sinus tracts. Evidence level: guideline‑based recommendation 65

Alternative Systemic Options When Deep Lesions Are Absent

• Oral tetracyclines (doxycycline 100 mg once or twice daily or lymecycline 408 mg once daily) for 12 weeks may be used for more extensive mild disease or early Hurley Stage II without deep inflammatory lesions. In the only available randomized trial, tetracycline monotherapy achieved ≈30 % reduction in abscess count, indicating limited efficacy for deep lesions. Evidence level: single RCT (moderate‑quality) 65

Treatment Duration and Monitoring

• Complete the full 10–12‑week course before reassessment; evaluation should include pain visual‑analogue scale (VAS), inflammatory lesion count, and Dermatology Life Quality Index (DLQI). Evidence level: guideline‑based recommendation 65
• Response assessment uses the Hidradenitis Suppurativa Clinical Response (HiSCR) criterion (≥50 % reduction in abscess/nodule count with no increase in abscesses or draining fistulas). Evidence level: guideline‑based recommendation 65
• After the course, institute a treatment break to gauge the need for further therapy and to mitigate antimicrobial‑resistance risk. Evidence level: guideline‑based recommendation 65

Baseline Screening Prior to Antibiotic Initiation

• Perform baseline screening for depression, anxiety, and cardiovascular‑risk factors (e.g., diabetes, hypertension, hyperlipidaemia). Evidence level: guideline‑based recommendation 65

Critical Pitfalls to Avoid (Evidence‑Based Safety Guidance)

• Do not use doxycycline or other tetracycline monotherapy as first‑line for Hurley Stage II with abscesses, because they have minimal impact on deep inflammatory lesions. Evidence level: guideline‑based warning 65
• Do not continue any antibiotic beyond 12 weeks without formal reassessment, as prolonged use raises resistance without proven additional benefit. Evidence level: guideline‑based warning 65
• Do not rely on topical clindamycin alone for Hurley Stage II, since it only reduces superficial pustules and does not address nodules or abscesses. Evidence level: guideline‑based warning 65

Breastfeeding Considerations for Clindamycin Use in Hidradenitis Suppurativa

Safety Monitoring

• The American Academy of Dermatology advises caution when prescribing oral clindamycin to breastfeeding patients with hidradenitis suppurativa, as it may increase the risk of gastrointestinal side effects in the infant; alternative antibiotics such as amoxicillin‑clavulanic acid, erythromycin, azithromycin, or metronidazole should be considered. 66

Doxycycline Use in Hidradenitis Suppurativa – Evidence‑Based Recommendations

Indications and First‑Line Therapy

• Oral doxycycline 100 mg once or twice daily for 12 weeks is an appropriate first‑line oral antibiotic for mild‑to‑moderate hidradenitis suppurativa (Hurley Stage I or mild Stage II without deep abscesses)【67】.
• Topical clindamycin 1 % solution or gel applied twice daily for 12 weeks, combined with a benzoyl‑peroxide wash, is recommended as the initial first‑line therapy for isolated nodules without sinus tracts【67】.
• If topical therapy fails or disease is more widespread but still mild, escalation to oral doxycycline 100 mg once or twice daily for 12 weeks is advised【67】.
• For moderate disease (Hurley Stage II with recurrent nodules and limited sinus tracts), the preferred first‑line regimen is clindamycin 300 mg twice daily plus rifampicin 300–600 mg daily for 10–12 weeks, achieving response rates of 71‑93 % and markedly superior to doxycycline【67】.

Treatment Duration and Monitoring

• Initiate a 12‑week doxycycline course and then reassess disease activity using pain visual analogue scale, inflammatory lesion count (nodules + abscesses), number of flares in the prior month, and Dermatology Life Quality Index (DLQI)【67】.
• After completing the 12‑week course, implement a treatment break to evaluate the need for continued therapy and to mitigate antimicrobial‑resistance risk【67】.

Escalation Pathways

• When no clinical response is observed after 12 weeks of doxycycline, transition to clindamycin 300 mg twice daily plus rifampicin 300–600 mg daily for 10–12 weeks【67】.
• If the clindamycin‑rifampicin combination fails after 12 weeks, escalate to adalimumab (160 mg week 0, 80 mg week 2, then 40 mg weekly) or refer for specialist evaluation of other biologics (secukinumab, ustekinumab, infliximab) or surgical intervention【67】.

Adjunctive Lifestyle and Comorbidity Management

• Refer all patients for smoking‑cessation support; 70‑75 % of hidradenitis suppurativa patients are smokers, and tobacco use worsens outcomes【67】.
• Provide weight‑management counseling for patients with elevated BMI; obesity prevalence exceeds 75 % in this population【67】.
• Offer NSAIDs for pain control as part of symptomatic management【67】.
• Use appropriate wound dressings for draining lesions to promote healing and reduce secondary infection【67】.
• Screen for depression, anxiety, and cardiovascular risk factors (blood pressure, lipid profile, HbA1c) because these comorbidities are highly prevalent in hidradenitis suppurativa patients【67】.

Surgical Management and Comorbidity Screening in Hidradenitis Suppurativa

Surgical Interventions

• Deroofing is recommended for patients with recurrent nodules and sinus‑tract tunnels as a targeted procedure to remove the epithelialized tunnel lining and reduce disease burden. 68
• Wide local excision using scalpel, CO₂ laser, or electrosurgical techniques—performed with or without subsequent reconstruction—is appropriate for extensive, chronic HS lesions that involve large areas of skin and subcutaneous tissue. 68

Comorbidity Screening

• All individuals with HS should be screened for inflammatory bowel disease, especially Crohn disease, by reviewing gastrointestinal symptoms and, when indicated, pursuing appropriate diagnostic work‑up. 68

Evidence‑Based Recommendations for Refractory Hidradenitis Suppurativa Lesions

Wound‑Care Optimization

• Use absorptive foam dressings or hydro‑fiber (e.g., Aquacel) rather than petroleum‑based dressings for draining sinus tracts.
  Evidence: Observational study in the Journal of the American Academy of Dermatology (2019) reported higher patient‑reported satisfaction and better management of exudate with these advanced dressings. Strength of evidence: moderate (prospective cohort). 69

• Do not employ collagen‑based dressings (e.g., gentamicin‑collagen sponges) for HS surgical or sinus‑tract wounds.
  Evidence: A randomized controlled trial of 200 patients showed no difference in 3‑month recurrence rates compared with standard saline‑based wound care (Risk Ratio = 0.96; 95 % CI 0.68–1.34). Strength of evidence: high (RCT). 69

Adalimumab Dosing Guidance

• Weekly administration of adalimumab 40 mg is required for moderate‑to‑severe HS; the every‑other‑week regimen is ineffective.
  Evidence: Clinical data published in the British Journal of Dermatology (2019) demonstrated lack of clinical response with the bi‑weekly schedule, supporting weekly dosing as the minimum effective regimen. Strength of evidence: moderate (prospective clinical study). 70

Guideline Summary for Diagnosis and Management of Hidradenitis Suppurativa

Diagnosis

• Clinical diagnostic triad – diagnosis requires (1) typical lesions (painful nodules, abscesses, sinus tracts, bridged scars, or open comedones), (2) typical anatomic sites (axillae, groin, perineal/perianal region, inframammary or intermammary folds, buttocks), and (3) a chronic‑recurrent course. [BAD, AAD] [71]
• Key lesion morphology – look for paired (“double‑headed”) comedones, painful subcutaneous nodules, rupturing abscesses with thick foul‑smelling fluid, dermal sinus tracts/tunnels, and rope‑like fibrotic scarring. [BAD] [71]
• Typical distribution – systematically examine intertriginous areas: axillae (most common), inguinal/genital region, perianal/perineal area, sub‑/inter‑mammary folds, buttocks, medial thighs, and posterior auricular region. [BAD, AAD] [71]72
• Chronicity markers – recurrent episodes (≥2 within 6 months), long‑standing symptoms, and presence of scarring or contractures support the diagnosis. [BAD] [71]
• Pain assessment – record baseline pain using a 0–10 Visual Analog Scale (VAS); severe pain is a cardinal symptom. [BAD, AAD] [71][73][72]
• Limited utility of routine testing – bacterial cultures are unnecessary unless secondary infection (cellulitis, fever, systemic signs) is evident; mixed normal flora does not guide therapy. [AAD] [73]72
• Genetic/biomarker testing not indicated – despite identified γ‑secretase mutations in familial cases, these tests have no current diagnostic role. [AAD] [73]
• Histopathology not required – HS is a clinical diagnosis; skin biopsy is optional only when alternative diagnoses are considered. [BAD, AAD] [71]72

Severity Staging

• Hurley staging system – recommended for its simplicity and direct treatment guidance. [AAD] [73]72
  
  • Stage I – isolated nodules/abscesses, minimal or no scarring, no sinus tracts. [AAD] [73]72
  • Stage II – recurrent nodules with one or a limited number of sinus tracts and scarring confined to a single body region. [AAD] [73]72
  • Stage III – multiple/extensive sinus tracts and scarring involving an entire anatomic region. [AAD] [73]72

Baseline Documentation

• Record Hurley stage per affected region (axillae, groin, etc.). [no citation – omitted]
• Count inflammatory lesions (nodules + abscesses) to establish a baseline for HiSCR monitoring. [BAD, AAD] [71][73][72]
• Measure pain using the VAS (0–10). [BAD, AAD] [71][73][72]
• Assess quality of life with the Dermatology Life Quality Index (DLQI). [BAD, AAD] [71][73][72]

Mandatory Comorbidity Screening

• Smoking – document pack‑years and refer for cessation; 70–75 % of HS patients smoke, with an odds ratio of ~36 versus controls. [BAD] [71]
• Diabetes – obtain HbA1c or fasting glucose; HS patients have a 1.5–3‑fold increased diabetes risk, prevalence up to 30 %. [BAD] [71]
• Cardiovascular risk – measure blood pressure, lipids, and BMI; HS nearly doubles cardiovascular mortality risk. [BAD, AAD] [71]73
• Psychiatric comorbidity – screen for depression and anxiety; rates of depression and completed suicide are higher in HS. [BAD, AAD] [71]73
• Inflammatory bowel disease – review gastrointestinal symptoms; strong association with Crohn disease (not ulcerative colitis). [BAD] [71]
• Malignancy – examine chronic perineal and buttock lesions for squamous cell carcinoma, the most frequent malignancy in these sites. [BAD] [71]

Treatment by Hurley Stage

Stage I (Mild)

• Topical clindamycin 1 % solution/gel applied twice daily to all affected areas for 12 weeks. [BAD, AAD] [71][73][72]
• Intralesional triamcinolone (10 mg/mL, 0.2–2 mL per lesion) for acutely inflamed nodules, providing rapid relief within 24 h. [AAD] [73]72

Stage II (Moderate)

• Oral clindamycin 300 mg BID + rifampicin 300–600 mg QD or BID for 10–12 weeks; reported response rates 71–93 %. [BAD, AAD] [71][73][72]
• This regimen is significantly superior to tetracycline monotherapy, which yields only ~30 % abscess reduction. [AAD] [73]72
• Doxycycline 100 mg once or twice daily for 12 weeks may be used for widespread mild disease or mild Stage II without deep lesions (not first‑line for Stage II with abscesses). [BAD, AAD] [71][73][72]

Stage III (Severe)

• Adalimumab induction: 160 mg SC week 0, 80 mg SC week 2, then 40 mg SC weekly from week 4 onward. [BAD, AAD] [71][73][72]
• HiSCR response (≥50 % reduction in abscess/nodule count without new abscesses or draining fistulas) achieved in 42–59 % of patients at week 12. [BAD] [71]
• Bridge therapy – while awaiting specialist evaluation or biologic approval, use clindamycin + rifampicin as above. [BAD] [71]
• Combined medical‑surgical approach – adding surgical excision to adalimumab improves clinical effectiveness versus adalimumab alone. [BAD] [71]

Monitoring & Escalation

• 12‑week reassessment – evaluate pain VAS, inflammatory lesion count, flare frequency, and DLQI. [BAD, AAD] [71][73][72]
• HiSCR measurement (≥50 % reduction in abscess/nodule count with no increase in new lesions). [BAD, AAD] [71][73][72]
• Post‑antibiotic treatment break – after completing a 10–12‑week antibiotic course, pause therapy to assess need for continuation and limit antimicrobial resistance. [BAD, AAD] [71]73
• Do not extend antibiotics beyond 12 weeks without formal reassessment, as prolonged use raises resistance without proven benefit. [AAD] [73]
• Escalation pathway:
  
  • Failure of clindamycin + rifampicin → start adalimumab. [BAD, AAD] [71]73
  • Failure of adalimumab after 16 weeks → consider second‑line biologics: infliximab 5 mg/kg (weeks 0, 2, 6, then q2 months), secukinumab (response 64.5–71.4 % in adalimumab‑failure patients), or ustekinumab. [BAD, AAD] [71]73

Surgical Management

• Radical wide excision for extensive disease with sinus tracts and scarring after failure of systemic therapy; achieves non‑recurrence rates ≈ 81 %. [BAD] [71]
• Wound‑closure options – secondary intention, split‑thickness skin grafts, or local flaps (e.g., thoracodorsal artery perforator flap). [BAD] [71]

Essential Adjunctive Measures (All Stages)

• Lifestyle & supportive care – refer all patients for smoking‑cessation, weight‑management (if BMI elevated), NSAID analgesia, appropriate wound dressings, depression/anxiety screening, and cardiovascular risk assessment. [BAD, AAD] [71]73
• Smoking cessation improves outcomes; tobacco use is linked to poorer disease control and treatment failure. [BAD] [71]
• Obesity prevalence > 75 % in HS, with an odds ratio of ~33 compared with controls; weight loss is critical for disease improvement. [BAD] [71]

Special Populations

• Pediatric (≥12 years) – adalimumab is FDA‑approved with weight‑based dosing for moderate‑to‑severe disease. [AAD] [73]
• Pediatric (≥8 years) – oral doxycycline is recommended when systemic antibiotics are needed. [AAD] [73]

Contraindicated / Ineffective Interventions

• Cryotherapy or microwave ablation – not recommended for acute HS lesions. [BAD] [71]